RVPH (Reviva Pharmaceuticals Holdings) Forward Dividend Yield % : 0.00% (As of May. 04, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Forward Dividend Yield %?

As of today (2025-05-04), the Forward Annual Dividend Yield of Reviva Pharmaceuticals Holdings is 0.00%.

As of today (2025-05-04), the Trailing Annual Dividend Yield of Reviva Pharmaceuticals Holdings is 0.00%.

RVPH's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.54
* Ranked among companies with meaningful Forward Dividend Yield % only.

Reviva Pharmaceuticals Holdings's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Reviva Pharmaceuticals Holdings's Forward Dividend Yield %

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Forward Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Reviva Pharmaceuticals Holdings Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Reviva Pharmaceuticals Holdings (NAS:RVPH) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Reviva Pharmaceuticals Holdings Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Reviva Pharmaceuticals Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10080 N. Wolfe Road, Suite SW3-200, Cupertino, CA, USA, 95014

Website

https://www.revivapharma.com

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Executives

Purav Patel	director	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu	officer: Chief Financial Officer	19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp	10 percent owner	250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena	director, 10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc	director, 10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat	director, 10 percent owner, officer: President and CEO	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon	officer: Chief Medical Officer	19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin	director	19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019